semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-74.0,  Breast Cancer Samples that fulfill all of the will be evaluated for the study Samples of women aged greater than or equal to (>/=) 18 and less than (<) 75 years Tumor samples already diagnosed based on the IHC score of 0 to +3 Samples of primary lesions excluding lymph nodes percent (%) neutral buffered formalin-fixed and paraffin embedded tissue samples  Samples that fulfill any of the below will not be included in the study Non-invasive ductal carcinoma (NOS) samples Tru-cut biopsies Non-breast cancer pathological samples
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Nail Abnormalities Age 18 years old or above 2. Being diagnosed nail surface abnormalities stably more than 3 months  Having severe or uncontrolled concomitant diseases 2. Having nail infection 3. History of manicure within the last 1 month 4. Use of Biotin or other nail modifying drugs within the previous 3 months 5. Pregnancy or lactation
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Neoplasm Carcinoma, Ductal, Breast Carcinoma, Intraductal, Noninfiltrating Female patients at least 21 years old Patients with invasive ductal carcinoma staged T1 or T2 with estrogen receptor and progesterone receptor positive (ER+/PR+) who are scheduled for sentinel lymph node biopsy Patients with Ductal Carcinoma In Situ (DCIS) (high or low grade) who are scheduled for sentinel lymph node biopsy including Patients having a mastectomy Patients with palpable DCIS Patients undergoing breast conservation with large (>5cm) area of DCIS Patients with signed consent to participate  Preoperative palpable axillary lymphadenopathy Preoperative ultrasound demonstrating suspicious adenopathy Previous axillary dissection or previous lymph node biopsy Patients with Invasive Lobular Carcinoma Patients who are pregnant
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Choledocholithiasis Bile Duct Diseases Bile Duct Carcinoma Patients 18 years of age or older Patients with choledocholithiasis, benign biliary strictures, malignant biliary strictures Biliary pathology suggested or confirmed by imaging with abdominal ultrasonography, CT scan, MRI/MRCP scan, or endoscopic ultrasonography (EUS)  Pregnancy (self reported) Presence of cholangitis before ERCP Prior history of surgery on the stomach or duodenum that precludes conventional ERCP or prior biliary tree surgery (not including cholecystectomy) Failure to selectively cannulate the bile duct Life expectancy less than 30 days Prisoners Patients unable to give consent
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Breast Cancer histologically confirmed primary breast cancer by core needle biopsy or excisional biopsy 2. abnormal para-sentinel lymph node was found by ultrasound examination 3. ultrasound-guided fine needle aspiration cytology of these nodes were performed 4. the result of fine needle aspiration cytology was negative (no tumour cell was found) 5. patient planed to perform SLNB  pathological diagnosed ductal carcinoma in situ by excisional biopsy 2. the result of fine needle aspiration cytology was positive 3. patient has received neo-adjuvant system therapy
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Breast Cancer Postmenopausal women (one year after menses stop) 2. Confirmed diagnosis of breast cancer 3. Tumors with higher expression PR > 50 % measured by IHC and PRA/RPB ratio equal or higher than 1.5 measured by WB 4. All clinical stages with tumor size greater than 1.5 cm to allow obtaining material from biopsy cores 5. OMS condition: 1 Adequate function of organs and systems Hematopoietic parameters Hemoglobin: 10 gr/mL Neutrophil counting: 1.500/mm3 CD4 counting: 400/mm3 Platelets counting: 100.000/mm3 Liver parameters Total albumin: 1.5 fold normal limit AST/ALT: 1.5 fold normal limit Renal Creatinine: 1.5 fold normal limit 6. Absence of other controlled disease 7. Patients willing to sign consent  Patients with no recommended surgery 2. Patients which have received any other treatment for this cancer 3. Patients expressing ER but expressing PRA/PRB levels lower than 1.5 4. Hepatitis infection (HBV o HCV) 5. HIV infection. 6. Cognitive alterations which limit the understanding of the protocol or compliance to the protocol 7. Prolonged QT/QTc basal interval
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Osteoarthritis Arthroplasty Patients undergoing unilateral primary total hip arthroplasty by Dr. James Verner at Beaumont Hospital Royal Oak Have a diagnosis of primary osteoarthritis (i.e. degenerative joint disease) Surgical approach is anterior  Minors (age less than 18 years) Pregnant (surgically sterile, post-menopausal, or negative blood test) Previous ipsilateral hip surgery Lumbar instrumentation Acute trauma Rheumatoid arthritis Avascular necrosis Hip dysplasia Known sensitivity, allergy, or contraindication to anesthetics being used in the study Narcotic sensitivity
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Samples derived from men and women of age greater than or equal to (>/=) 18 years Samples derived from participants with any stage of histologically confirmed invasive breast cancer with HER2 diagnostics performed within routine (histo-)pathological workup or (Histo-)Pathological work-up of the tumor sample as at or after start of this study Available information on the year of birth of the participant No pre-selection of tumor samples is allowed. Tumor samples have to be documented consecutively in the order of their (histo-)pathological work-up  Sample derived from participants with any stage of breast cancer with no HER2 diagnostics performed at the time of routine (histo-)pathological work-up Samples derived prior to the start of this study
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Eligible to receive chemotherapy and endocrine therapy as defined by a good Karnofsky index (≥80) and no hematologic, cardiologic or hepatic contraindications, nor any impeding comorbidity Informed consent form signed on the same day or before enrollment ≥ 18 years of age at time of consent Per study arm Histologically proven invasive stage I and II breast cancer and Hormone Receptor positive (ER+ PR-, ER PR+ or ER+ PR+) according to local standards & HER2 negative: IHC 0-1+, or FISH or other ISH non-amplified (locally assessed) IMPACt study; version 1 2015 September 1 Page 10 Axillary lymph node status: 0-3 involved (macro metastases i.e. >2mm OR micro metastases i.e. >0.2-2mm) OR Histologically proven invasive T1a or T1b breast cancer & Hormone receptor negative (ER- and PR-) according to local standards & HER2 negative: IHC 0-1+, or FISH or other ISH non-amplified (locally assessed) & Axillary lymph node status: 0-1 involved (macro metastases i.e. >2mm OR micro metastases i.e. >0.2-2mm) OR Histologically proven invasive T1a or T1b breast cancer & Hormone receptor negative or positive (ER-PR-, ER+PR-, ER-PR+, ER+PR+) according to local standards & HER2 positive: IHC 3+, or FISH or other ISH amplified (locally assessed) & Axillary lymph node status: 0-1 involved (macro metastases i.e. >2mm OR micro metastases i.e. >0.2-2mm)  Previous diagnosis of breast malignancy unless disease free for 10 years Metastatic disease Tumor sample shipped to Agendia with ≤ 30% tumor cells or that fails QA or QC Women who have started or completed adjuvant chemotherapy or neo-adjuvant chemotherapy for current breast cancer
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Infiltrating Bladder Urothelial Carcinoma Histologically confirmed muscle-invasive urothelial cancer (no histology will be excluded) No pelvic nodal metastases or distant metastases (based on computed tomography [CT], positron emission tomography [PET] or magnetic resonance imaging [MRI]) Karnofsky performance status (KPS) >= 70 Ability to understand, and willingness to sign, the written informed consent Patient will have either opted for bladder-sparing treatment as compared to radical cystectomy, or deemed medically inoperable Following the recent recommendations from the International Consultation on Urological Diseases-European Association of Urology International Consultation on Bladder Cancer, eligible patients will be those with no hydronephrosis, no extensive carcinoma in situ (CIS), and no tumor invasion into the stroma of the prostate  Patients with any evidence of distant metastases Prior pelvic radiotherapy History of Crohn's disease or ulcerative colitis Unable to receive chemotherapy Histologies other than urothelial (eg. squamous cell carcinoma, adenocarcinoma, small cell)
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 40.0-64.0,  Healthy Volunteers Female greater than or equal to 40 years Presenting to UM Breast Center and BWMC for breast imaging: screening or diagnostic mammogram, breast ultrasound (US), breast MRI, stereotactic core needle biopsy, ultrasound core needle biopsy, MRI guided breast biopsy Patients with a recent screening diagnosis of breast cancer < = 3months Patients presenting with mammogram findings with of 0-6 < =3 months Able to understand and the willingness to sign a written informed consent document  Patients with a personal history of stage 0-4 breast cancer >3months Patients who have known severe and/or uncontrolled medical or psychiatric conditions or other conditions that could affect their participation in the study, or personal history of other malignancies Patients who are unfit or unable to comply with having breast imaging studies such as mammogram, ultrasound, and MRI or breast biopsy or with study procedures-blood draw Patients with personal history of ovarian cancer or other cancers Patients with a personal history of breast biopsy positive for atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS)
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  Breast Neoplasms Histological diagnosis of invasive or in-situ ductal carcinoma (DCIS) Treated by breast conserving surgery with axillary node dissection (with a minimum of 6 nodes sampled) or sentinel lymph node biopsy Surgical margins clear for invasive carcinoma (no tumor at ink margin) or superior or equal to 2 mm for in-situ ductal carcinoma (DCIS) A maximum tumor size of 3 cm Age ≥50 years old Informed consent signed if participating in the Registry  No previous cancer unless in remission for more than 2 years Active auto immune disorder with severe vasculitis component Uncontrolled and complicated insulin-dependent diabetes Pregnancy Cosmetic breast implants Psychiatric or addictive disorder that would preclude attending follow-up Post-operative breast infection requiring prolonged antibiotic therapy Lobular features on histology (pure or mixed) or sarcoma histology Node macroscopically positive on axillary dissection or in the sentinel lymph node biopsy Extensive in
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Breast Cancer The patients signed the written informed consent The patients present with non-metastatic unilateral invasive ER-positive, HER2-negative breast cancer with a primary breast tumor > 2cm by imaging or an axillary lymph node > 2cm by imaging Postmenopausal women with age less than 70 years old The patients have no history of hormone therapy, chemotherapy, breast cancer surgery and radiotherapy The patients have normal cardiac functions by echocardiography The patients' ECOG scores are ≤2 The patients can swallow pills The results of patients' blood tests are as follows Hb≥90g/L WBC≥4E+9/L  The patients have other cancers at the same time or have the history of other cancers except controlled skin basal cell carcinoma or skin squamous cell carcinoma or carcinoma in situ of cervix uterus The patients have active infections that were not suitable for chemotherapy The patients have severe non-cancerous diseases The patients have bilateral breast cancers or multifocal breast cancers or inflammatory breast cancers The patients have a history of previous treatment with mTOR inhibitors The patients are undergoing current administration of anti-cancer therapies, or are attending other clinical trials The patients are in some special conditions that they cannot understand the written informed consent, such as they are demented or hawkish The patients have allergic history or contraindication of any of the interventional drugs
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Estrogen Receptor Negative HER2/Neu Negative Progesterone Receptor Negative Triple-Negative Breast Carcinoma The patient has proven TNBC, defined by standard pathologic assays as negative for estrogen receptor (ER) and progesterone receptor (PR) (< 10% tumor staining) and negative for human epidermal growth factor 2 (HER2) (immunohistochemistry [IHC] score < 3, gene copy number not amplified) TNBC patients who are previously untreated and enrolled in the prospective Institutional Review Board (IRB) approved clinical trial: 2014-0185 Patients who are able to understand and give consent to participating in the study  Is pregnant (confirmed by the patient as imaging clinic standard of care) or nursing mother Has lesions involving chest wall Has known allergy to Tc99m sestamibi Has known contraindications to MRI Has contraindication to MRI contrast